Name: AmerisourceBergen Corp. (NYSE:ABC) | Income Statement (Quarterly)
Creator: Stock Analysis on Net

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Download chart

AmerisourceBergen Corp., consolidated income statement (quarterly data)

US$ in thousands

3 months ended:	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016
Revenue	66,947,043)	63,457,205)	62,846,832)	61,174,149)	60,064,601)	57,719,446)	59,628,810)	58,912,421)	53,405,695)	49,154,171)	52,516,556)	49,244,768)	45,366,777)	47,417,639)	47,864,742)	45,637,802)	45,239,265)	43,319,602)	45,392,452)	43,297,136)	43,142,309)	41,033,858)	40,466,332)	39,120,015)	38,707,144)	37,147,402)	38,169,265)
Cost of goods sold	(64,682,397)	(61,161,763)	(60,700,879)	(59,188,590)	(58,049,232)	(55,484,366)	(57,568,451)	(56,843,010)	(51,517,489)	(47,620,790)	(51,064,326)	(47,897,921)	(44,141,061)	(46,029,532)	(46,633,528)	(44,453,065)	(44,008,026)	(41,894,846)	(44,094,872)	(42,264,495)	(41,930,968)	(39,778,175)	(39,353,680)	(37,947,995)	(37,627,269)	(35,890,975)	(37,131,585)
Gross profit	2,264,646)	2,295,442)	2,145,953)	1,985,559)	2,015,369)	2,235,080)	2,060,359)	2,069,411)	1,888,206)	1,533,381)	1,452,230)	1,346,847)	1,225,716)	1,388,107)	1,231,214)	1,184,737)	1,231,239)	1,424,756)	1,297,580)	1,032,641)	1,211,341)	1,255,683)	1,112,652)	1,172,020)	1,079,875)	1,256,427)	1,037,680)
Distribution, selling, and administrative	(1,304,141)	(1,321,087)	(1,290,928)	(1,263,462)	(1,212,152)	(1,203,238)	(1,170,110)	(1,215,688)	(913,414)	(730,081)	(735,068)	(720,966)	(666,885)	(693,413)	(685,953)	(721,944)	(656,943)	(628,036)	(656,585)	(657,805)	(626,548)	(617,426)	(558,522)	(560,877)	(525,463)	(521,843)	(520,547)
Depreciation	(104,504)	(100,681)	(99,542)	(97,323)	(97,189)	(96,498)	(95,585)	(95,289)	(82,320)	(75,270)	(73,945)	(71,553)	(69,594)	(69,796)	(69,244)	(72,668)	(71,716)	(75,219)	(75,362)	(73,899)	(72,447)	(72,718)	(64,907)	(64,017)	(59,478)	(57,751)	(55,854)
Amortization	(169,768)	(140,785)	(72,398)	(73,239)	(74,925)	(78,792)	(80,344)	(82,432)	(44,781)	(25,527)	(25,608)	(25,784)	(25,821)	(23,999)	(35,271)	(35,877)	(35,880)	(48,547)	(47,138)	(46,659)	(47,598)	(46,670)	(40,229)	(40,318)	(40,041)	(39,918)	(40,226)
Litigation and opioid-related (expenses) credit	67,102)	(15,813)	(12,706)	29,404)	(67,870)	(52,090)	(32,635)	(96,410)	(226,964)	(78,156)	(70,381)	(6,641,681)	(58,585)	(67,732)	(39,309)	(174,407)	(60,006)	(55,389)	(40,672)	(40,497)	(75,553)	(37,449)	(30,021)	(641,810)	(284,517)	(11,934)	(21,066)
Acquisition, integration, and restructuring expenses	(83,207)	(156,557)	(37,236)	(126,420)	—)	(24,305)	(32,334)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Impairment of assets	—)	—)	—)	—)	—)	—)	(4,946)	(11,324)	—)	—)	—)	—)	—)	(223,652)	(138,000)	—)	—)	(570,000)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Goodwill impairment	—)	—)	—)	—)	(75,936)	—)	—)	(6,373)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(59,684)	—)	—)	—)	—)	—)	—)	—)
Operating expenses	(1,594,518)	(1,734,923)	(1,512,810)	(1,531,040)	(1,528,072)	(1,454,923)	(1,415,954)	(1,507,516)	(1,267,479)	(909,034)	(905,002)	(7,459,984)	(820,885)	(1,078,592)	(967,777)	(1,004,896)	(824,545)	(1,377,191)	(819,757)	(878,544)	(822,146)	(774,263)	(693,679)	(1,307,022)	(909,499)	(631,446)	(637,693)
Operating income (loss)	670,128)	560,519)	633,143)	454,519)	487,297)	780,157)	644,405)	561,895)	620,727)	624,347)	547,228)	(6,113,137)	404,831)	309,515)	263,437)	179,841)	406,694)	47,565)	477,823)	154,097)	389,195)	481,420)	418,973)	(135,002)	170,376)	624,981)	399,987)
Other income (loss), net	(3,436)	15,720)	6,328)	(20,656)	41,888)	948)	5,172)	46,637)	4,141)	(23,310)	14,268)	4,387)	(1,073)	1,109)	(2,842)	1,213)	342)	14,494)	(3,097)	820)	3,158)	(29,123)	(324)	(1,228)	(1,398)	5,233)	123)
Interest expense, net	(57,864)	(64,109)	(46,016)	(51,523)	(52,862)	(52,916)	(53,372)	(54,596)	(51,338)	(34,526)	(33,614)	(34,707)	(37,748)	(34,421)	(31,007)	(36,403)	(35,921)	(43,275)	(42,170)	(43,047)	(47,151)	(48,637)	(35,864)	(35,311)	(35,603)	(37,299)	(36,972)
Loss on consolidation of equity investments	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(42,328)	—)	—)	—)	—)	—)
Loss on early retirement of debt	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(22,175)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(23,766)	—)	—)	—)	—)
Income (loss) before income taxes	608,828)	512,130)	593,455)	382,340)	476,323)	728,189)	596,205)	553,936)	573,530)	566,511)	527,882)	(6,143,457)	343,835)	276,203)	229,588)	144,651)	371,115)	18,784)	432,556)	111,870)	345,202)	361,332)	359,019)	(171,541)	133,375)	592,915)	363,138)
Income tax (expense) benefit	(129,615)	(83,917)	(117,285)	(83,664)	(113,120)	(172,944)	(146,789)	(117,488)	(278,082)	(132,506)	(149,175)	1,298,952)	(56,567)	694,908)	(43,020)	(12,344)	(69,113)	9,289)	(40,803)	82,134)	(67,327)	(79,172)	502,834)	(173,046)	(83,023)	(181,442)	(115,892)
Net income (loss)	479,213)	428,213)	476,170)	298,676)	363,203)	555,245)	449,416)	436,448)	295,448)	434,005)	378,707)	(4,844,505)	287,268)	971,111)	186,568)	132,307)	302,002)	28,073)	391,753)	194,004)	277,875)	282,160)	861,853)	(344,587)	50,352)	411,473)	247,246)
Net (income) loss attributable to noncontrolling interests	368)	7,189)	3,575)	(3,939)	43,761)	(7,231)	(311)	1,250)	(3,326)	1,262)	(3,862)	(1,567)	2,171)	(10,834)	1,072)	312)	(43)	(938)	1,899)	39,284)	(2,066)	5,295)	—)	—)	—)	—)	—)
Net income (loss) attributable to AmerisourceBergen Corporation	479,581)	435,402)	479,745)	294,737)	406,964)	548,014)	449,105)	437,698)	292,122)	435,267)	374,845)	(4,846,072)	289,439)	960,277)	187,640)	132,619)	301,959)	27,135)	393,652)	233,288)	275,809)	287,455)	861,853)	(344,587)	50,352)	411,473)	247,246)

Revenue exhibits a consistent long-term upward trajectory, growing from 38.17 billion USD in December 2016 to 66.95 billion USD by June 2023. This expansion is mirrored by a corresponding increase in the cost of goods sold, maintaining a tight relationship characteristic of the pharmaceutical distribution sector. Gross profit followed a general growth pattern, rising from approximately 1.04 billion USD in late 2016 to 2.26 billion USD in mid-2023, although quarterly fluctuations are evident.

Revenue and Gross Margin Trends: A steady increase in top-line growth is observed, with revenue expanding by approximately 75% over the analyzed period. Gross profit margins remained relatively thin but showed an overall improvement in absolute terms, peaking at 2.29 billion USD in March 2023. This suggests a capacity to scale operations while maintaining a baseline of profitability despite the high cost of inventory.
Operating Expense Analysis: Distribution, selling, and administrative expenses increased significantly, rising from 520.55 million USD in December 2016 to 1.30 billion USD in June 2023. This growth reflects the increasing operational complexity and scale of the organization. Depreciation and amortization expenses also trended upward, with a notable spike in amortization starting in 2021, potentially linked to acquisition-related intangible assets.
Impact of Non-Recurring Items: The most significant financial anomaly occurred in the quarter ending September 30, 2020, where a litigation and opioid-related expense of 6.64 billion USD was recorded. This single event resulted in a substantial operating loss of 6.11 billion USD and a net loss of 4.84 billion USD for that period. Other periodic impacts include impairment of assets and goodwill impairments, most notably a 570 million USD impairment in March 2019 and 75.94 million USD in September 2022.
Operating and Net Income Performance: Excluding the 2020 litigation shock, operating income demonstrated resilience and growth, recovering from the 2020 low to reach 670.13 million USD by June 2023. Net income exhibited high volatility due to significant shifts in income tax benefits and expenses. For example, a substantial tax benefit of 1.30 billion USD in September 2020 partially offset the litigation loss. In the most recent quarters, net income attributable to the corporation has stabilized between 294 million USD and 555 million USD.
Financial Structure and Other Costs: Interest expenses remained relatively stable between 30 million USD and 64 million USD per quarter, though a slight increase is noted in more recent years. Acquisition, integration, and restructuring expenses became a recurring factor from 2021 onward, indicating a period of active corporate restructuring or strategic acquisitions.

The overall financial trend indicates a company successfully scaling its revenue base while managing significant one-time legal liabilities. The recovery of operating income following the 2020 litigation event suggests a return to operational stability and an improvement in the underlying profitability of the core business model.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

AmerisourceBergen Corp. (NYSE:ABC)

Income StatementQuarterly Data

Income Statement
Quarterly Data